市場調査レポート
商品コード
1386506
原発性免疫不全症治療市場レポート:2030年までの動向、予測、競合分析Primary Immunodeficiency Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
原発性免疫不全症治療市場レポート:2030年までの動向、予測、競合分析 |
出版日: 2023年10月11日
発行: Lucintel
ページ情報: 英文 150 Pages
納期: 3営業日
|
原発性免疫不全症治療の動向と予測
世界の原発性免疫不全症治療市場は、2024年から2030年までのCAGRが6.3%で、2030年までに推定111億米ドルに達すると予測されます。この市場の主な促進要因は、原発性免疫不全症に対する認識の高まり、ゲノム研究の活発化、遺伝子検査、フローサイトメトリー、次世代シーケンシングなどの診断技術の継続的進歩です。世界の原発性免疫不全症治療市場の将来は、免疫グロブリン補充療法、幹細胞/骨髄移植、抗生物質療法、遺伝子治療市場にビジネスチャンスがあり、有望視されています。
原発性免疫不全症治療市場の洞察
Lucintelの予測では、抗体欠乏症に対する認識が高まっていること、高齢化により抗体欠乏症に罹患しやすくなっていることから、抗体欠乏症が引き続き最大セグメントとなります。
この市場の中では、免疫グロブリン補充療法が免疫系機能の改善に役立ち、原発性免疫不全症患者の感染症リスクを軽減することから、最大セグメントであり続けると予測されます。
北米は、原発性免疫不全症の有病率が高く、原発性免疫不全症治療に対する償還が可能であることから、今後も最大セグメントであり続けると思われます。
Primary Immunodeficiency Therapeutics Trends and Forecast
The future of the global primary immunodeficiency therapeutics market looks promising with opportunities in the immunoglobulin replacement therapy, stem cell/bone marrow transplantation, antibiotic therapy, and gene therapy markets. The global primary immunodeficiency therapeutics market is expected to reach an estimated $11.1 billion by 2030 with a CAGR of 6.3% from 2024 to 2030. The major drivers for this market are increasing primary immunodeficiency disorders awareness, rising genomic research, and on-going advancement in diagnostoc technologies, such as genetic testing, flow cytometry, and next-generation sequencing.
A more than 150-page report is developed to help in your business decisions.
Primary Immunodeficiency Therapeutics by Segment
The study includes a forecast for the global primary immunodeficiency therapeutics by type, disease type, and region.
Primary Immunodeficiency Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:
Primary Immunodeficiency Therapeutics Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:
Primary Immunodeficiency Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:
List of Primary Immunodeficiency Therapeutics Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies primary immunodeficiency therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the primary immunodeficiency therapeutics companies profiled in this report include-
Primary Immunodeficiency Therapeutics Market Insights
Lucintel forecasts that antibody deficiency will remain the largest segment due to increasing awareness of antibody deficiency and aging population is more susceptible to antibody deficiency.
Within this market, immunoglobulin replacement therapy is expected to remain the largest segment as it helps to improve the immune system function and also reduces the risk of infections in primary immunodeficiency disorders patients.
North America will remain the largest segment due to high prevalence of primary immunodeficiency disorders and availability of reimbursement for primary immunodeficiency disorders therapeutics.
Features of the Global Primary Immunodeficiency Therapeutics Market
Market Size Estimates: Primary immunodeficiency therapeutics market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Primary immunodeficiency therapeutics market size by type, disease type, and region in terms of value ($B).
Regional Analysis: Primary immunodeficiency therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, disease types, and regions for the primary immunodeficiency therapeutics market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the primary immunodeficiency therapeutics market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q.1 What is the primary immunodeficiency therapeutics market size?
Answer: The global primary immunodeficiency therapeutics market is expected to reach an estimated $11.1 billion by 2030.
Q.2 What is the growth forecast for primary immunodeficiency therapeutics market?
Answer: The global primary immunodeficiency therapeutics market is expected to grow with a CAGR of 6.3% from 2024 to 2030.
Q.3 What are the major drivers influencing the growth of the primary immunodeficiency therapeutics market?
Answer: The major drivers for this market are increasing primary immunodeficiency disorders awareness, rising genomic research, and on-going advancement in diagnostoc technologies, such as genetic testing, flow cytometry, and next-generation sequencing.
Q4. What are the major segments for primary immunodeficiency therapeutics market?
Answer: The future of the primary immunodeficiency therapeutics market looks promising with opportunities in the immunoglobulin replacement therapy, stem cell/bone marrow transplantation, antibiotic therapy, and gene therapy markets.
Q5. Who are the key primary immunodeficiency therapeutics market companies?
Answer: Some of the key primary immunodeficiency therapeutics companies are as follows:
Q6. Which primary immunodeficiency therapeutics market segment will be the largest in future?
Answer: Lucintel forecasts that antibody deficiency will remain the largest segment due to increasing awareness of antibody deficiency and aging population is more susceptible to antibody deficiency.
Q7. In primary immunodeficiency therapeutics market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest segment due to high prevalence of primary immunodeficiency disorders and availability of reimbursement for primary immunodeficiency disorders therapeutics.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.